Mark Lanasa
About Mark Lanasa
Mark Lanasa is the SVP, Chief Medical Officer, Solid Tumors at BeiGene, with extensive experience in clinical development and leadership roles in oncology.
Current Role at BeiGene
Mark Lanasa currently serves as the SVP, Chief Medical Officer for Solid Tumors at BeiGene. He joined the company in February 2022. In this role, he is responsible for overseeing the development and strategy for solid tumor oncology programs. His expertise in clinical development and leadership is integral to advancing BeiGene's mission in the oncology sector.
Previous Experience at AstraZeneca
Before joining BeiGene, Mark Lanasa held several key positions at AstraZeneca from 2017 to 2022. He served as Vice President and Enhertu Global Clinical Head, Late Phase R&D, where he played a pivotal role in the development of Enhertu, a treatment for HER2-positive breast cancer. He also contributed significantly to the field of immuno-oncology as the Global Clinical Lead. Mark’s efforts at AstraZeneca underscored his capacity to lead late-phase research and development projects.
Background in Clinical Development at MedImmune and Immunocore
Mark Lanasa has extensive experience in clinical development from his tenure at MedImmune and Immunocore. At MedImmune, he shifted roles from Associate Medical Director to Director of Clinical Development between 2014 and 2016. He later served as Senior Director of Clinical Development at Immunocore from 2016 to 2017, contributing to the development of Kimmtrak (tebentafusp-tebn), a T-cell engager.
Academic Contributions and Early Career at Duke University
Mark Lanasa's academic career includes significant contributions during his time at Duke University. He was part of the faculty in hematologic malignancies, serving as an Assistant Professor from 2008 to 2013 and as an Associate Professor in 2013. His early academic roles laid a strong foundation for his later work in clinical development within the pharmaceutical industry.
Educational Background and Medical Training
Mark Lanasa holds a comprehensive educational background in medicine and science. He earned his Bachelor of Science in Chemistry from Penn State University in 1995. He then completed both his M.D. and Ph.D. in Biochemistry and Molecular Biology at the University of Pittsburgh School of Medicine. Further, he completed his residency and post-graduate fellowship at Duke University Medical Center, focusing on hematologic malignancies.